SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines shares are facing significant volatility as investors weigh strong underlying travel demand and premium revenue growth against the operational headwinds of an ongoing government shutdown. The community is actively debating the potential for long-term recovery versus short-term risks, with many traders closely monitoring the impact of flight capacity reductions and staffing shortages on the airline's near-term earnings potential.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Canton is gaining traction as community members highlight its role in enterprise blockchain and RWA tokenization, bolstered by recent exchange listings and institutional interest. Investors are closely watching the project's utility and long-term potential, often comparing it to established assets while debating its supply dynamics and technical roadmap.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure and intense community scrutiny following a fraud lawsuit regarding the company's acquisition strategy and persistent regulatory investigations. Investors are actively debating the stock's future, weighing potential AI-driven growth and upcoming product announcements against concerns over falling EV demand, market volatility, and eroding trust in company leadership.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors react to a prolonged period of downward price action and institutional sell walls, while the community remains divided between those calling the project a failed utility and loyalists holding for potential breakthroughs tied to the Clarity Act and stablecoin legislation. Sentiment is heavily impacted by the lack of direct developer communication, leading to intense debate over whether current price levels represent a historical accumulation opportunity or the final stages of a declining asset.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is gaining momentum on the Solana blockchain as investors highlight its community-driven, locked supply model and consistent development efforts over several months. Community members are actively rallying around the project's long-term conviction and potential for growth, positioning it as a standout in the current memecoin market.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is trending upward following successful clinical trial results for its Zepbound and Mounjaro treatments, which outperformed Novo Nordisk's experimental obesity drug CagriSema in a head-to-head comparison. The community is actively discussing this shift in market leadership, with many investors viewing the development as a clear catalyst for Lilly's continued dominance in the lucrative GLP-1 weight-loss sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its upcoming one-year anniversary and anticipation for April 20th, emphasizing its role as a cultural movement rooted in long-term persistence rather than typical memecoin hype. Supporters are actively sharing educational content regarding the endocannabinoid system and industrial cannabis applications while doubling down on their conviction in the project's decentralized, community-driven mission.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is currently trending as investors focus on its potential as essential infrastructure for tokenized banking and cross-border settlement, with the community closely tracking its integration with major global financial institutions. Despite recent price volatility, supporters remain vocal about its limited token supply and the anticipation of upcoming network features like staking and real-world adoption, while others express frustration over its long-term consolidation and lack of explosive movement compared to broader market trends.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is currently a major focus for investors as it is viewed as a primary beneficiary of market share displacement in the AI server sector, particularly following the regulatory and accounting controversies surrounding Supermicro. The community is actively debating Dell's ability to absorb enterprise demand, with bullish sentiment highlighting its deep integration with Nvidia and scale, while some traders closely monitor for potential volatility heading into earnings.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant investor attention driven by anticipation of the company's expanding ophthalmic platform and upcoming product launches, particularly the highly anticipated move for Vevye to Tier 1 coverage. Community discourse is heavily focused on the stock's potential for long-term growth and eventual valuation, with many bullish participants actively accumulating shares during price dips based on their confidence in the company's product pipeline and the belief that the current market price significantly undervalues its long-term revenue trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 13,976 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP David Dieter sold 13,976 shares of the firm's stock in a transaction dated Wednesday, March 18th. The shares were sold at an average...

Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright

HC Wainwright reissued a "buy" rating and set a $60.00 target price on shares of Collegium Pharmaceutical in a research report on Friday...

Needham & Company LLC Reiterates Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Needham & Company LLC reaffirmed a "buy" rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday...

Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up   - Should You Buy?

Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up - Still a Buy...

Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037

Collegium Pharmaceutical (NASDAQ:COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a transaction the company said would add a second commercial-stage ADHD product alongside Jornay PM and extend the durability of its ADHD revenue base...

Collegium Pharmaceutical To Acquire AZSTARYS For At Least $650 Mln From Corium Therapeutics

(RTTNews) - Collegium Pharmaceutical, Inc. (COLL), a biopharmaceutical company, Thursday announced that it has agreed to acquire AZSTARYS for $650 million in cash from Corium Therapeutics Holdings, a...

Collegium Pharmaceutical, Inc. $COLL Position Reduced by Eventide Asset Management LLC

Eventide Asset Management LLC trimmed its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 9.5% in the third quarter, according to its most recent disclosure with the...

Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference

Collegium Pharmaceutical (NASDAQ:COLL) highlighted a record-breaking 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong performance from newly acquired ADHD...

Jefferies Financial Group Inc. Takes $4.43 Million Position in Collegium Pharmaceutical, Inc. $COLL

Jefferies Financial Group Inc. acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with...

Citigroup Inc. Decreases Stock Holdings in Collegium Pharmaceutical, Inc. $COLL

Citigroup Inc. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 97.5% in the third quarter, according to its most recent filing with the Securities and...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

COLL
Collegium Pharmaceutical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest COLL News

COLLCollegium Pharmaceutical Inc